Aclaris Therapeutics, Inc.
ACRSStock
$5.36+243.67%52W
Market Cap$746.50M
P/E—
Div yield—
Beta0.79
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)96.23%
Price vs S&P 500 (4W)24.94%
VGM Score49.35
Market Capitalization$746.50M
Earnings Surprise History
Q1 26-0.15est. -0.16
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.27
4.31
4.35
4.33
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ACRSAclaris Therapeutics, Inc. | D | C | A | $5.36 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing immuno-inflammatory disease therapies, including candidates Zunsemetinib (an Oral MK2 Inhibitor), Lepzacitinib, ATI-2138 (an ITJ Inhibitor), and ATI-052. The company also operates a contract research segment providing laboratory services, though therapeutics drives the majority of revenue.